Kexing Biopharm Co., Ltd. (SHA:688136)

Kexing Biopharm Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	492.69	554.56	568.8	785.38	877.62	1,103
Cash & Short-Term Investments	612.79	554.56	568.8	785.38	877.62	1,103
Cash Growth	30.88%	-2.50%	-27.58%	-10.51%	-20.41%	630.43%
Accounts Receivable	768.68	563.82	342.04	387.44	382.62	407.86
Other Receivables	18.55	15.9	4.45	3.25	2.84	5.34
Receivables	787.23	579.72	346.49	390.69	385.46	413.2
Inventory	124.74	141.81	191.36	208.18	172.16	113.38
Other Current Assets	25.31	11.72	26.97	27.06	25.57	14.69
Total Current Assets	1,550	1,288	1,134	1,411	1,461	1,644
Property, Plant & Equipment	1,115	1,177	1,200	1,053	936.24	585.86
Long-Term Investments	250.9	203.41	245.32	15	247.46	-
Other Intangible Assets	235.99	225.14	158.72	165.82	26.96	36.85
Long-Term Accounts Receivable	-	-	-	0.31	-	-
Long-Term Deferred Tax Assets	116.71	117.22	133.98	80.83	12.1	3.75
Long-Term Deferred Charges	80.12	50.37	3.08	-	21.82	14.69
Other Long-Term Assets	62.11	101.02	156.61	438.91	123.64	81.55
Total Assets	3,411	3,162	3,031	3,165	2,829	2,367
Accounts Payable	201.38	71.91	56.02	67.78	65.73	41.23
Accrued Expenses	14.75	112.98	84.14	92.89	97.63	88.32
Short-Term Debt	267.48	269.12	120.7	162.69	276.26	204.57
Current Portion of Long-Term Debt	478.67	313.25	275.03	51.78	-	1.36
Current Portion of Leases	-	12.45	6.7	19.87	18.39	15.6
Current Income Taxes Payable	11.74	-	-	-	-	-
Current Unearned Revenue	11.42	9.78	20.44	17.99	7.16	4.76
Other Current Liabilities	47.21	96.91	106.97	126.36	138.44	84.86
Total Current Liabilities	1,033	886.4	669.99	539.37	603.61	440.7
Long-Term Debt	649.43	611.18	695.84	779.23	263.37	94.19
Long-Term Leases	2.5	14.78	17.79	24.96	43.25	-
Long-Term Unearned Revenue	4.28	3.15	5.32	0.75	0.99	1.61
Long-Term Deferred Tax Liabilities	6.34	7.48	11.36	14.55	7.12	-
Total Liabilities	1,695	1,523	1,400	1,359	918.34	536.5
Common Stock	201.26	199.64	199.2	198.7	198.7	198.7
Additional Paid-In Capital	1,318	1,288	1,282	1,274	1,266	1,266
Retained Earnings	272.27	176.78	145.3	335.59	445.76	365.19
Treasury Stock	-78.5	-31.12	-	-	-	-
Comprehensive Income & Other	1.03	1.11	-0.01	-	-	-
Total Common Equity	1,714	1,635	1,626	1,808	1,911	1,830
Minority Interest	2.18	4.34	4.77	-2.53	-	-
Shareholders' Equity	1,716	1,639	1,631	1,806	1,911	1,830
Total Liabilities & Equity	3,411	3,162	3,031	3,165	2,829	2,367
Total Debt	1,398	1,221	1,116	1,039	601.27	315.72
Net Cash (Debt)	-785.28	-666.22	-547.26	-253.16	276.35	786.93
Net Cash Growth	-	-	-	-	-64.88%	-
Net Cash Per Share	-3.88	-3.39	-2.76	-1.26	1.40	5.26
Filing Date Shares Outstanding	198.11	197.76	199.2	198.7	198.7	198.7
Total Common Shares Outstanding	198.11	197.76	199.2	198.7	198.7	198.7
Working Capital	517.43	401.41	463.63	871.94	857.2	1,203
Book Value Per Share	8.65	8.27	8.16	9.10	9.62	9.21
Tangible Book Value	1,478	1,410	1,467	1,643	1,884	1,793
Tangible Book Value Per Share	7.46	7.13	7.37	8.27	9.48	9.03
Buildings	-	754.25	662.95	609.2	361.78	354.23
Machinery	-	514.22	370.42	326.3	243.82	198.49
Construction In Progress	-	176.82	372.56	256.57	428.52	168.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.